慕思健康睡眠股份有限公司 关于公司部分经销商增持公司股份计划的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、增持计划的规模：本次拟增持股份金额不低于人民币 3,500 万元，不超过 人民币 7,000 万元。 2、增持计划的价格：本次增持不设定价格区间，由增持计划管理人根据对 慕思健康睡眠股份有限公司（以下简称"公司"）股票价值的合理判断，并结合 二级市场波动情况独立判断买卖时点和价格，择机逐步实施增持计划。 证券代码：001323 证券简称：慕思股份 公告编号：2023-056 2、截止本公告披露日，增持主体持有公司股份 1,126,876 股，占公司总股本 的 0.28%。 二、增持计划的主要内容 1、增持股份的目的：基于对公司未来发展前景的信心以及对公司投资价值 的认同，公司部分经销商拟在二级市场增持公司股票，分享公司发展成果，实现 公司长远发展与经销商利益的结合。 2、增持股份的种类：公司无限售流通 A 股股份。 3、增持计划的期限：自 2023 年 8 月 26 日起 6 个月内，且承诺增持期间不 减持。 4、增持计划 ...

证券代码：001323 证券简称：慕思股份 公告编号：2023-055 慕思健康睡眠股份有限公司 关于公司为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 （一）本次担保的基本情况 为满足公司生产经营活动的需要，慕思健康睡眠股份有限公司（以下简称"慕 思股份"或"公司"）于 2023 年 11 月 20 日与上海浦东发展银行股份有限公司 东莞分行（以下简称"浦发银行"或"融资行"）签署了《最高额保证合同》（以 下简称"担保合同"），分别为全资子公司东莞慕思寝具销售有限公司（以下简 称"慕思销售"）、东莞慕思寝具电子商务有限公司（以下简称"慕思电商"）、 东莞市艾慕寝室用品有限公司（以下简称"东莞艾慕"）向融资行申请的授信融 资提供连带责任保证担保，具体明细如下： | 授信单位/被担保人 | 担保人 | 授信银行/债权人 | 授信金额/担保金额/万元 | | --- | --- | --- | --- | | 慕思销售 | 慕思股份 | 浦发银行 | 30,000 | | 慕思电商 | 慕思股份 | 浦发银行 | 6, ...

证券代码：001323 证券简称：慕思股份 公告编号：2023-054 慕思健康睡眠股份有限公司 关于以集中竞价交易方式首次回购公司股份 暨回购进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 慕思健康睡眠股份有限公司（以下简称"公司"）于 2023 年 9 月 4 日分别 召开第二届董事会第一次会议和第二届监事会第一次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金通过深圳 证券交易所交易系统以集中竞价交易方式回购部分公司股份，本次回购股份将用 于后期实施股权激励计划或员工持股计划。本次回购股份的种类为公司发行的 A 股社会公众股份，回购资金总额不低于人民币 12,000 万元（含），不超过人民 币 24,000 万元（含），回购价格不超过人民币 40 元/股（含）；按回购金额上限 人民币 24,000 万元、回购价格上限 40 元/股测算，回购股份数量为 600 万股，约 占公司目前总股本的 1.50%；按回购金额下限人民币 12,000 万元、回购价格上限 40 元/股测算，回购股份数量为 300 万股，约 ...

慕思健康睡眠股份有限公司（以下简称"公司"）董事会于 2023 年 10 月 31 日收到公司副总经理杨鑫先生提交的书面辞职报告。杨鑫先生因个人原因， 申请辞去公司副总经理职务，辞职后不再担任公司及下属公司任何职务。截至本 公告披露之日，杨鑫先生未持有公司股份，亦不存在应当履行而未履行的承诺事 项。 证券代码：001323 证券简称：慕思股份 公告编号：2023-053 慕思健康睡眠股份有限公司 关于副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》等法律法规和《公司章程》的有关规定， 杨鑫先生的《辞职报告》自送达公司董事会之日起生效。杨鑫先生的辞职不会影 响公司的正常经营。公司董事会对杨鑫先生在担任副总经理期间勤勉尽责的工作 及为公司所做出的贡献表示衷心的感谢！ 特此公告。 慕思健康睡眠股份有限公司 董事会 2023 年 11 月 01 日 ...

Financial Performance - In the first three quarters of 2023, the company achieved operating revenue of 3.805 billion CNY, a year-on-year decrease of 8.38% [2] - Net profit attributable to shareholders was 1.284 billion CNY, a year-on-year increase of 21.44% [2] - Gross margin was 50.79%, an increase of 4.32 percentage points year-on-year [2] - Net margin was 13.62%, an increase of 3.34 percentage points year-on-year [2] Q3 2023 Highlights - In Q3 2023, the company reported operating revenue of 1.406 billion CNY, a year-on-year increase of 0.33% [4] - Excluding the impact of direct supply to the Opai brand, revenue growth was 16.74% [4] - Net profit attributable to shareholders in Q3 was 163 million CNY, a year-on-year increase of 37.43% [4] - Gross margin for Q3 was 50.98%, up 3.70 percentage points year-on-year [4] - Net margin for Q3 was 11.57%, an increase of 3.12 percentage points year-on-year [4] Revenue Breakdown - For the first three quarters of 2023, revenue from various channels was as follows: - Distribution: 2.899 billion CNY (up 4.70%) - E-commerce: 640 million CNY (up 23.35%) - Direct supply: 142 million CNY (down 76.57%) - Direct sales: 103 million CNY (down 54.37%) [4] Cost Management - R&D expenses for the first three quarters were 135 million CNY, an increase of 25.17% year-on-year [4] - Financial expenses were -45 million CNY, a decrease of 594.94% year-on-year [4] - The reduction in financial expenses was attributed to cost-cutting measures and improved efficiency in fund usage [4] Cash Flow and Assets - As of September 30, 2023, the company had cash and cash equivalents of 3.808 billion CNY, indicating sufficient liquidity [5] - Total assets reached 7.140 billion CNY, a year-on-year increase of 22.78% [2] - Shareholder equity was 4.481 billion CNY, a year-on-year increase of 2.77% [2] Future Outlook - The company plans to continue growth in Q4 2023 through joint marketing activities and major promotional events [5] - New store openings and renovations are part of the strategy to enhance store efficiency and customer value [5]

本次变更不影响招商证券对公司的持续督导工作。本次保荐代表人变更后， 公司首次公开发行股票项目的持续督导保荐代表人为张燚先生和汤玮女士，持续 督导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义务结束 为止。 公司董事会对邓永辉先生在公司首次公开发行股票项目以及持续督导期间 所做出的贡献表示衷心感谢！ 特此公告。 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 慕思健康睡眠股份有限公司（以下简称"公司"）于近日收到保荐机构招商 证券股份有限公司（以下简称"招商证券"）出具的《关于更换保荐代表人的函》。 招商证券作为公司首次公开发行股票项目的保荐机构，原指派的保荐代表人为邓 永辉先生、张燚先生。现因邓永辉先生工作拟发生变动，不再适合继续履行公司 首次公开发行股票项目的持续督导职责。为保证持续督导工作的有序进行，招商 证券决定指派汤玮女士（简历详见附件）自 2023 年 10 月 31 日起接替邓永辉先 生履行公司首次公开发行股票项目的剩余督导期的持续督导工作事宜。 证券代码：001323 证券简称：慕思股份 公告编号：2 ...

Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥1.41 billion, a slight increase of 0.33% compared to ¥1.40 billion in the same period last year[15] - Net profit attributable to shareholders for Q3 2023 reached ¥162.62 million, representing a significant increase of 37.43% from ¥118.29 million year-on-year[15] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥155.88 million, up 46.93% from ¥106.06 million in the previous year[15] - Basic earnings per share for Q3 2023 were ¥0.41, an increase of 36.67% from ¥0.30 in the same period last year[15] - The total comprehensive income for the period attributable to the parent company's owners was CNY 520,700,633.01, compared to CNY 436,046,030.94 in the previous period, representing an increase of approximately 19.4%[30] - Basic and diluted earnings per share for the period were both CNY 1.30, up from CNY 1.19 in the previous period, indicating an increase of about 9.24%[30] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥1.28 billion, a remarkable increase of 1,269.44% compared to ¥93.79 million in the same period last year[15] - The net cash flow from operating activities for the third quarter was approximately ¥1.28 billion, a significant increase compared to ¥93.79 million in the previous period, indicating strong operational performance[50] - Total cash inflow from investment activities reached approximately ¥701.56 million, compared to ¥203.56 million in the previous period, reflecting improved investment recovery[50] - The net cash flow from financing activities was negative at approximately -¥254.84 million, contrasting with a positive inflow of ¥1.03 billion in the previous period, suggesting increased cash outflows for debt repayment and dividends[50] - The total cash and cash equivalents at the end of the period amounted to approximately ¥3.20 billion, up from ¥2.11 billion at the end of the previous period, indicating a strong liquidity position[50] - The company reported a total cash outflow from operating activities of approximately ¥3.67 billion, down from ¥4.41 billion in the previous period, showing improved cost management[50] - Cash received from investment income was approximately ¥1.35 million, an increase from ¥985,205.48, indicating better investment performance[50] - The company received approximately ¥634.91 million in cash from borrowings, which was not present in the previous period, indicating a strategy to leverage debt for growth[50] Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥7.14 billion, reflecting a 22.78% increase from ¥5.81 billion at the beginning of the year[15] - Total assets reached CNY 7,139,715,199.99, compared to CNY 5,814,964,146.63 in the previous year, reflecting a growth of 22.73%[27] - Total liabilities increased to CNY 2,658,554,908.29, up 82.73% from CNY 1,454,494,487.94 year-over-year[27] - The equity attributable to shareholders at the end of the reporting period was approximately ¥4.48 billion, a 2.77% increase from ¥4.36 billion at the beginning of the year[15] - The company’s total equity attributable to shareholders reached CNY 4,481,160,291.70, up from CNY 4,360,469,658.69 in the previous year, indicating a growth of 2.77%[27] Operational Metrics - Cash and cash equivalents increased by 115.01% to ¥3.81 billion, primarily due to cash flow generated from operating activities[18] - Accounts receivable decreased by 83.08% to $32,495,917.40 due to a reduction in short-term credit to distributors and a decrease in direct supply business[19] - Prepayments increased by 40.07% to $189,402,098.68 primarily due to an increase in advance payments for major materials[19] - Inventory rose by 42.91% to $314,685,449.43 as a result of an increase in finished goods[19] - Construction in progress surged by 89.01% to $401,681,918.48 due to increased investment in building projects and automation equipment[19] - Short-term borrowings increased by 100.00% to $193,000,000.00, reflecting a rise in short-term loans[19] - Contract liabilities grew by 39.67% to $164,050,877.56, mainly due to an increase in advance payments received from distributors[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,144[23] - The company approved a share repurchase plan on September 4, 2023, and has opened a dedicated securities account for this purpose[22] - The company has a diverse shareholder base, with significant holdings from various institutional investors, including China Life Insurance and other funds[39] - The actual controllers of the company are Wang Bingkun and Lin Jiyong, who hold significant stakes in related investment entities[39] Regulatory and Accounting Changes - The company is implementing new accounting standards starting from January 1, 2023, which may affect financial reporting[33] - The third quarter report has not been audited, indicating that the figures are preliminary and subject to change[35] Government Support - The company received government subsidies amounting to ¥6.91 million during the reporting period, contributing to its overall financial performance[7]

证券代码：001323 证券简称：慕思股份 公告编号：2023-049 慕思健康睡眠股份有限公司（以下简称"公司"）第二届监事会第二次会议 由监事会主席罗振彪先生召集，会议通知于 2023 年 10 月 20 日以邮件、微信、 电话的方式送达全体监事，并于 2023 年 10 月 26 日下午 15:00 以现场方式在公 司会议室召开。本次会议应出席监事 3 人，实际出席监事 3 人，会议由监事会主 席罗振彪先生主持，公司董事会秘书赵元贵先生列席本次会议。本次会议的出席 人数、召集、召开程序和议事内容均符合《中华人民共和国公司法》等相关法律 法规以及《公司章程》等的有关规定，会议形成的决议合法有效。 二、监事会会议审议情况 经各位监事认真审议，会议形成了如下决议： （一）审议通过《关于公司<2023 年第三季度报告>的议案》 经审核，监事会认为：董事会编制和审核公司《2023 年第三季度报告》的 程序符合有关法律、行政法规、规范性文件及《公司章程》的相关规定，报告内 容能够真实、准确、完整地反映公司的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 慕思 ...

证券代码：001323 证券简称：慕思股份 公告编号：2023-047 慕思健康睡眠股份有限公司 关于变更持续督导保荐代表人的公告 公司董事会对康自强先生在公司首次公开发行股票项目以及持续督导期间 所做出的贡献表示衷心感谢！ 特此公告。 慕思健康睡眠股份有限公司 董事会 2023 年 10 月 27 日 附件： 张燚先生简历 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 慕思健康睡眠股份有限公司（以下简称"公司"）于近日收到保荐机构招商 证券股份有限公司（以下简称"招商证券"）出具的《关于更换保荐代表人的函》。 招商证券作为公司首次公开发行股票项目的保荐机构，原指派的保荐代表人为邓 永辉先生、康自强先生。现因康自强先生工作拟发生变动，不再适合继续履行公 司首次公开发行股票项目的持续督导职责。为保证持续督导工作的有序进行，招 商证券决定指派张燚先生（简历详见附件）自 2023 年 10 月 27 日起接替康自强 先生履行公司首次公开发行股票项目的剩余督导期的持续督导工作事宜。 本次变更不影响招商证券对公司的持续督导工作。本次保荐代表人变更后， 公司首次公开发行 ...

证券代码：001323 证券简称：慕思股份 公告编号：2023-048 慕思健康睡眠股份有限公司 第二届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 具体内容详见公司同日刊登在《证券时报》《证券日报》《中国证券报》《上 海证券报》《经济参考报》及巨潮资讯网（http://www.cninfo.com.cn）的《2023 年第三季度报告》（公告编号：2023-050）。 （二）审议通过《关于聘任公司内部审计负责人的议案》 一、董事会会议召开情况 慕思健康睡眠股份有限公司（以下简称"公司"）第二届董事会第二次会议 由董事长王炳坤先生召集，会议通知于 2023 年 10 月 20 日以邮件、微信、电话 的方式送达全体董事，并于 2023 年 10 月 26 日下午 14:00 以现场及通讯的方式 在公司会议室召开。本次会议应出席董事 7 人，实际出席董事 7 人。会议由董事 长王炳坤先生主持，公司监事及高级管理人员列席了会议。本次会议的出席人数、 召集、召开程序和议事内容均符合《中华人民共和国公司法》等相关法律法规和 《公司章程》的有关规 ...